With the growing numbers of nanomaterials (NMs), there is a great demand for rapid and reliable ways of testingNMsafety—preferably usingin vitroapproaches, to avoid the ethical dilemmas associated with animal research. Data are needed for developing intelligent testing strategies for risk assessment ofNMs, based on grouping and read‐across approaches. The adoption of high throughput screening (HTS) and high content analysis (HCA) forNMtoxicity testing allows the testing of numerous materials at different concentrations and on different types of cells, reduces the effect of inter‐experimental variation, and makes substantial savings in time and cost.HTS/HCAapproaches facilitate the classification of key biological indicators ofNM‐cell interactions. Validation ofin vitroHTStests is required, taking account of relevance toin vivoresults.HTS/HCAapproaches are needed to assess dose‐ and time‐dependent toxicity, allowing prediction ofin vivoadverse effects. SeveralHTS/HCAmethods are being validated and applied forNMtesting in theFP7projectNANoREG, including Label‐free cellular screening ofNMuptake, HCA, High throughput flow cytometry, Impedance‐based monitoring, Multiplex analysis of secreted products, and genotoxicity methods—namely High throughput comet assay, High throughputin vitromicronucleus assay, andγH2AXassay. There are several technical challenges withHTS/HCAforNMtesting, as toxicity screening needs to be coupled with characterization ofNMsin exposure medium prior to the test; possible interference ofNMswithHTS/HCAtechniques is another concern. Advantages and challenges ofHTS/HCAapproaches inNMsafety are discussed.WIREs Nanomed Nanobiotechnol2017, 9:e1413. doi: 10.1002/wnan.1413This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials

Advances in nanotechnology and its usage in various fields have led to the exposure of humans to engineered nanomaterials (NMs) and there is a need to tackle the potential human health effects before these materials are fully exploited. The main purpose of the current study was to assess whether aluminium oxide NMs (Al₂O₃-30 nm and Al₂O₃-40 nm) could cause potential genotoxic effects in vivo. Characterization of Al₂O₃-30 nm and Al₂O₃-40 nm was done with transmission electron microscopy, dynamic light scattering and laser Doppler velocimetry prior to their use in this study. The genotoxicity end points considered in this study were the frequency of micronuclei (MN) and the percentage of tail DNA (% Tail DNA) migration in rat peripheral blood cells using the micronucleus test (MNT) and the comet assay, respectively. Genotoxic effects were evaluated in groups of female Wistar rats (five per group) after single doses of 500, 1000 and 2000 mg/kg body weight (bw) of Al₂O₃-30 nm, Al₂O₃-40 nm and Al₂O₃-bulk. Al₂O₃-30 nm and Al₂O₃-40 nm showed a statistically significant dose-related increase in % Tail DNA for Al₂O₃-30 nm and Al₂O₃-40 nm (P < 0.05). However, Al₂O₃-bulk did not induce statistically significant changes over control values. The MNT also revealed a statistically significant (P < 0.05) dose-dependent increase in the frequency of MN, whereas Al₂O₃-bulk did not show any significant increase in frequency of MN compared to control. Cyclophosphamide (40 mg/kg bw) used as a positive control showed statistically significant (P < 0.001) increase in % Tail DNA and frequency of MN. The biodistribution of Al₂O₃-30 nm and Al₂O₃-40 nm and Al₂O₃-bulk in different rat tissues, urine and feces was also studied 14 days after treatment using inductively coupled plasma mass spectrometry. The data indicated that tissue distribution of Al₂O₃ was size dependent. Our findings suggest that Al₂O₃ NMs were able to cause size- and dose-dependent genotoxicity in vivo compared to Al₂O₃-bulk and control groups.

Despite being a relatively new field, nanoscience has been in the forefront among many scientific areas. Nanoparticle materials (NM) present interesting physicochemical characteristics not necessarily found in their bulky forms, and alterations in their size or coating markedly modify their physical, chemical, and biological properties. Due to these novel properties there is a general trend to exploit these NM in several fields of science, particularly in medicine and industry. The increased presence of NM in the environment warrants evaluation of potential harmful effects in order to protect both environment and human exposed populations. Although in vitro approaches are commonly used to determine potential adverse effects of NM, in vivo studies generate data expected to be more relevant for risk assessment. As an in vivo model Drosophila melanogaster was previously found to possess reliable utility in determining the biological effects of NM, and thus its usage increased markedly over the last few years. The aims of this review are to present a comprehensive overview of all apparent studies carried out with NM and Drosophila, to attain a clear and comprehensive picture of the potential risk of NM exposure to health, and to demonstrate the advantages of using Drosophila in nanotoxicological investigations.